- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02949089
ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects
October 27, 2016 updated by: Ache Laboratorios Farmaceuticos S.A.
An Open Label, Dose Escalation Study of ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects
This study intends to provide information on the safety and tolerability of repeated oral doses of ACH04.
A phase I, single-center, first in human, open-label, dose escalation study of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best address the study goals.
Study Overview
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ceará
-
Fortaleza, Ceará, Brazil, 60160140
- UNIFAC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subjects will be healthy males subjects between 18 and 50 years of age;
- Subjects must be in good healthy as determined by a medical history, physical examination and clinical laboratory evaluations;
- Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the stdy restrictions.
Exclusion Criteria:
- Subjects with hypersensitivity known to Psidium guajava L. or history of serious adverse events;
- Subjects who have a significant history of alcoholism or drug/chemical abuse;
- Subjects who have body mass index < 18 or > 30;
- Subjects who have received any medications that is known to have a toxic potential well defined in large organs within the past 3 months prior the study start;
- Subjets who doesn´t agree to use, for the duration of the study, a barrier contraceptive;
- Subjects who were hospitalized for any reason in the six week prior the study start;
- Subjects who, in the opinion of the investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol;
- Subjects who are participating in a clinical trial or have participated in a clinical study involving administration of an investigational drug, within one year;
- Subjects who are relatives of employees from the sponsor and the site, respectively;
- Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator;
- Any finding of clinical observation (anamnesis and physical evaluation), laboratory abnormality, who in the investigator opinion, may jeopardize the subjects or interfere with the study goals.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACH04
Dosage: 1 capsule, PO, 24/24h for 10 days.
|
The subjects will receive the study medication in each group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety of rising multiple doses of ACH04
Time Frame: up to 39 days
|
Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram
|
up to 39 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
May 3, 2011
First Submitted That Met QC Criteria
October 27, 2016
First Posted (Estimate)
October 31, 2016
Study Record Updates
Last Update Posted (Estimate)
October 31, 2016
Last Update Submitted That Met QC Criteria
October 27, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACH-PSD-01(04/11)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated